Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies
US10596257B2 · kind B2 · utility
1Cited by
36References
52Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 5, 2017 |
| Grant date | Mar 24, 2020 |
| Priority date | — |
| Expiry date | Jan 5, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides compositions and methods for treating CEA-positive cancers. The method comprising administering a PD-1 axis binding antagonist and a bispecific antibody that targets CEA and CD3.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.